Adalvo is pleased to announce the successful DCP approval for Vortioxetine Film-Coated Tablets.
The product has been developed based on the reference brand Brintellix, which is indicated for treating major depressive episodes and sold at around $1.7bn in 2022, with a CAGR of 6%, according to IQVIA. This product is being developed as part of a strategic collaboration with one of our partners.
We expect to be amongst the first-to-market companies in all our major markets based on our positive progress.
Partner up now!
At Adalvo, there are no half-measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
arni.baldursson@adalvo.com - Head of Global BD&L
camila.reinoso@adalvo.com - LATAM (exc. Brazil)
marta.puig@adalvo.com - South Europe
ajish.rajan@adalvo.com – Central & Eastern Europe, Russia & CIS
bruno.alves@adalvo.com - Brazil
jose.rendueles@adalvo.com- North Europe, APAC, MENA & Israel
marc.nolasco@adalvo.com - Central and Western Europe
paulo.rodriguez@adalvo.com – Europe
supreet.sharma@adalvo.com – UK/Ireland, North America & South Africa
Click on your preferred Business Partner and get in touch today!